Integrin Targeting Agents for Multi-Modality Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging techniques for assessing molecular endpoints in diseases are invasive and lack sensitivity, necessitating the development of noninvasive methods that can visualize specific molecular targets and pathways for enhanced diagnosis and treatment efficacy.
Innovation Solution
Development of integrin targeting agents with fluorescent and/or magnetic properties that selectively bind to αvβ3 integrin, enabling optical and multi-modality imaging, including optical imaging, magnetic resonance imaging, and nuclear imaging, to visualize angiogenesis and other physiological processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current imaging techniques (MRI, CT, ultrasound) are used, then anatomical and physiological information can be obtained, but the sensitivity and specificity for molecular targets are insufficient
Solution Approach 1:
The patent combines multiple imaging modalities (optical imaging with fluorescent probes, magnetic resonance imaging with paramagnetic agents, and nuclear imaging with radioactive isotopes) into a single multi-modality imaging agent. This merging approach enables simultaneous acquisition of molecular specificity from optical imaging, anatomical context from MRI, and functional information from nuclear imaging, thereby resolving the contradiction between measurement precision and device complexity.
Solution Approach 2:
The imaging agent is designed as a composite structure containing multiple functional components: a molecular targeting ligand (for specific binding to integrins or other molecular targets), a fluorescent probe (for optical detection), a paramagnetic agent (for MRI contrast), and a radioactive isotope (for nuclear imaging). This composite material approach allows a single agent to provide high sensitivity and specificity across multiple imaging modalities simultaneously.
2Measurement precision
If invasive tissue sampling and surgery are performed, then molecular endpoint assessment is possible, but patient morbidity and procedural complexity increase
Solution Approach 1:
The patent replaces invasive mechanical procedures (tissue biopsy, surgical sampling) with noninvasive imaging techniques. The multi-modality imaging agent can be administered systemically and will accumulate at molecular targets in vivo, allowing molecular endpoint assessment through external imaging detection without mechanical tissue disruption. This substitution eliminates patient morbidity while maintaining measurement precision.
Solution Approach 2:
The imaging agent serves as an intermediary substance that bridges the gap between internal molecular processes and external detection. The agent specifically binds to molecular targets (such as integrins in angiogenesis) and carries multiple imaging reporters, translating invisible molecular events into detectable signals across multiple modalities without requiring direct tissue sampling.
3Productivity
If optical imaging in the visible region is used, then imaging speed and cost-effectiveness are improved, but penetration depth and sensitivity are limited
Solution Approach 1:
The patent utilizes fluorophores with emission wavelengths in the red and near-infrared region (600-900 nm) rather than visible wavelengths. This parameter change in the optical spectrum is critical because biological tissues have minimal absorption and scattering in this wavelength range, allowing deep penetration while maintaining high detection sensitivity. The imaging can be performed rapidly (seconds to minutes) while achieving both deep tissue penetration and molecular-level sensitivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents provide stable, biocompatible solutions for in vivo and in vitro imaging, allowing for real-time molecular and functional information, enhancing the ability to diagnose and monitor disease states with improved sensitivity and specificity.
Implementation Method 1
optical probes can be designed as dynamic molecular imaging agents that may alter their reporting profiles in vivo to provide molecular and functional information in real time
Implementation Method 2
integrin targeting agents that can have fluorescent properties and/or magnetic properties (for example, paramagnetic or superparamagnetic properties) that can be used as MRI or multi-modality imaging agents
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3D
AI summary
The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.